IL1B and non-small cell lung carcinoma: On October 25, 2021, Novartis announced the anti-interleukin-1β (IL-1β) drug, canakinumab in non-small cell lung cancer (NSCLC) did not improve the primary endpoints of overall survival (OS) and progression-free survival (PFS) in the CANOPY-1 (NCT03631199) Phase III clinical trial [1].